Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Harvard Business School
Mallinckrodt
Johnson and Johnson

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR LIOTHYRONINE SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Liothyronine Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed Lucille P. Markey Cancer Center at University of Kentucky Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00027417 ↗ Study of Triostat in Infants During Heart Surgery Completed Michael Portman Phase 3 2001-04-01 This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery.
NCT00098852 ↗ Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status National Cancer Institute (NCI) Phase 2 2004-10-01 RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.
NCT00098852 ↗ Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status University of California, San Francisco Phase 2 2004-10-01 RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Liothyronine Sodium

Condition Name

Condition Name for Liothyronine Sodium
Intervention Trials
Head and Neck Cancer 2
Healthy 2
Congenital Heart Defects 1
Postoperative; Dysfunction Following Cardiac Surgery 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Liothyronine Sodium
Intervention Trials
Thyroid Diseases 4
Thyroid Neoplasms 3
Head and Neck Neoplasms 2
Heart Defects, Congenital 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Liothyronine Sodium

Trials by Country

Trials by Country for Liothyronine Sodium
Location Trials
United States 14
Korea, Republic of 1
Indonesia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Liothyronine Sodium
Location Trials
District of Columbia 2
Minnesota 2
Maryland 2
California 2
Washington 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Liothyronine Sodium

Clinical Trial Phase

Clinical Trial Phase for Liothyronine Sodium
Clinical Trial Phase Trials
Phase 3 3
Phase 2 4
Phase 1/Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Liothyronine Sodium
Clinical Trial Phase Trials
Completed 9
Recruiting 2
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Liothyronine Sodium

Sponsor Name

Sponsor Name for Liothyronine Sodium
Sponsor Trials
National Cancer Institute (NCI) 4
Ipe, LLC 2
Yonsei University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Liothyronine Sodium
Sponsor Trials
Other 14
NIH 4
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Boehringer Ingelheim
Dow
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.